Julian Adams, Ph.D., is president and chief executive officer of Stand Up To Cancer, and among the world's foremost oncology researchers. His long and distinguished career as a leader in drug discovery and development, both as a scientist and pharmaceutical industry senior executive, well prepared him to assume overall management responsibility for SU2C. Until his retirement in October 2022, Dr. Adams served as chief executive officer of Gamida Cell, a commercial-stage biopharmaceutical company working to develop cell therapies for blood cancers and rare, serious blood diseases. Prior to joining Gamida Cell, Dr. Adams was president of R&D at Infinity Pharmaceuticals, Inc., where he oversaw development of small molecule drugs to treat cancer. He is also a former member of SU2C's Scientific Advisory Committee. He holds more than 40 patents and has authored more than 130 papers and book chapters in peer-reviewed journals .Dr. Adams received his B.S. from McGill University and his Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. He also received the degree of Doctor of Science, honoris causa, from McGill University in 2012.